But with BMS wanting their drug to show increased efficacy they will be looking to the podium too.
CAVATAK appears to greatly improve both Merck's and BMS's product. Surely they will both want to have CAVATAK and avoid the other having it.
A bidding war could easily happen.
I know it has been a long wait for some holders, but we really are entering exciting times imho.
Ann: Viralytics to Present New CAVATAK Clinical Data at AACR, page-20
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)